medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2022, Number 2

<< Back

VacciMonitor 2022; 31 (2)

Anti-COVID-19 vaccines: a look from the regulatory perspective

Vázquez-Romero JE, Romeu-Álvarez B

Language: Spanish
References: 42
Page: 90-99
PDF size: 332.66 Kb.


ABSTRACT

The development of anti-COVID-19 vaccines has been one of the main priorities of the global scientific community. To date, multiple vaccines have been approved for use by numerous countries, and the World Health Organization has already included some of these in its emergency use listing program. This paper offers information on these aspects and analyzes the colossal challenge that facing the growing development of vaccines against COVID-19 has represented for the regulatory sector, ensuring their quality, safety and efficacy. Similarly, new approaches in the development of clinical trials are addressed, or modifications in existing regulatory procedures that have been carefully adapted by regulatory agencies, without losing their scrutiny capacity and the integrity of the scientific-regulatory evaluation.


REFERENCES

  1. World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Ginebra: OMS; 2020.Disponible en: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. (Consultado en línea: 3 octubre 2021).

  2. World Health Organization (WHO). WHO Coronavirus (COVID-19) Dashboard [homepage on the internet]. Ginebra: OMS; c2022-03. Disponible en: https://covid19.who.int/. (Consultado en línea: 28 marzo 2022).

  3. Francis MJ. Recent Advances in Vaccine Technologies. Vet Clin North Am Small Anim Pract. 2018; 48(2):231-41. doi: 10.1016/j.cvsm.2017.10.002.

  4. World Health Organization (WHO). COVID-19 vaccine tracker and landscape. [homepage on the internet]. Ginebra: OMS; c2021-12. Disponible en: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. (Consultado en línea: 14 de diciembre 2021).

  5. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021; 19:2508-17. doi: https://10.1016/j.csbj.2021.04.061.

  6. World Health Organization (WHO). Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process. Ginebra: WHO; 2021. Disponible en: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_11Nov2021.pdf. (Consultado en línea: 20 noviembre 2021).

  7. Food and Drug Administration. [homepage on the internet]. MD: FDA; c2020-12. Disponible en: https://www.fda.gov/vaccines-blood-biologics/vaccines. (Consultado en línea: 14 diciembre 2020).

  8. CECMED. Resolución CECMED No 156/2021, Modifica la Resolución No 144 de agosto del año 2021 del CECMED la cual otorgó la Autorización de Uso en Emergencia a la vacuna cubana SOBERANA102, de nombre genérico Vacuna anti COVID-19 conjugada de subunidad proteica, para ampliar su indicación en población pediátrica a partir de los 2 años de edad. La Habana: CECMED; 2021. Disponible en: https://www.cecmed.cu/reglamentacion/ambito-regulador/indice?field_instrumento_legal_value=&field_content_value=&page=0%. (Consultado en línea: 1 noviembre 2021).

  9. CECMED. Resolución CECMED 174/2021: Ampliación de la indicación de la vacuna cubana SOBERANA1PLUS, formulación con tiomersal a convalecientes de COVID-19, mayores de 19 años de edad, con 2 meses o más de su alta médica. La Habana: CECMED; 2021. Disponible en: https://www.cecmed.cu/node/6356. (Consultado en línea: 1 noviembre 2021).

  10. CECMED. Resolución CECMED No 202/2021: Modifica la Autorización de Uso en Emergencia a la vacuna cubana ABDALA 50 µg, de nombre genérico Vacuna COVID-19 de subunidad proteica, para ampliar su indicación en población pediátrica a partir de los 2 años de edad. La Habana: CECMED; 2021. Disponible en: https://www.cecmed.cu/reglamentacion/ambito-regulador/indice?field_instrumento_legal_value=&page=1%2C2. (Consultado en línea: 30 noviembre 2021).

  11. Wegner M. New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19: In Responding to a Global Health Crisis, Industry is Discovering New, Efficient Ways of Meeting Objectives. Ther Innov Regul Sci. 2021; 55(2):463-6. doi: https://10.1007/s43441-020-00239-8.

  12. Food and Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine [homepage on the internet]. MD: FDA; c2021-12. Disponible en: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine. (Consultado en línea: 12 diciembre 2021).

  13. Food and Drug Administration. Spikevax and Moderna COVID-19 Vaccine. [homepage on the internet]. MD: FDA; c2021-12. Disponible en: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine. (Consultado en línea: 12 diciembre 2021).

  14. Food and Drug Administration. Emergency use authorization for vaccines to prevent COVID-19: guidance for industry. MD: FDA; c2020-10. Disponible en: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-vaccines-prevent-covid-19. (Consultado en línea: 12 diciembre 2021).

  15. Marks P. What regulators must learn from COVID-19. Nat Med. 2021; 27:1858. doi: https://10.1038/s41591-021-01559-4.

  16. Prugger C, Spelsberg A, Keil U, Erviti J, Doshi P. Evaluating covid-19 vaccine efficacy and safety in the post-authorisation phase. BMJ. 2021; 375:e067570. doi: https://10.1136/bmj-2021-067570.

  17. Scheppler L, De Clercq N, McGoldrick M, Dias J. Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines. Vaccine. 2021;39(5):790-6. doi: https://10.1016/j.vaccine.2020.11.077.

  18. World Health Organization (WHO). Guidelines on regulatory preparedness for provision of the marketing authorization of human pandemic influenza vaccines in non-vaccine-producing countries. Geneva: WHO; 2016. Disponible en:https://www.who.int/biologicals/expert_committee/PIP_Non-producer_guide_BS_final-working_version-19102016-clean.pdf. (Consultado en línea: 12 diciembre 2021).

  19. Feldmann H, Feldmann F, Marzi A. Ebola: Lessons on Vaccine Development. Annu Rev Microbiol. 2018;72:423-46. doi: https://10.1146/annurev-micro-090817-062414.

  20. Wong G, Qiu X. Funding vaccines for emerging infectious diseases. Hum Vaccin Immunother. 2018;14(7):1760-2. doi: https://10.1080/21645515.2017.1412024.

  21. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R, et al, Oxford COVID Vaccine Trial Group. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021;27(2):270-8. doi: https://10.1038/s41591-020-01194-5. Errata en: Nat Med. 2021;27(6):1116. doi: https://10.1038/s41591-021-01363-0.

  22. Barrett JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, Folegatti PM, Gilbride C, et al, Oxford COVID Vaccine Trial Group. Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021;27(2):279-8. doi: https://10.1038/s41591-020-01179-4. Errata en: Nat Med. 2021;27(6):1113. doi: https://10.1038/s41591-021-01372-z.

  23. World Health Organization (WHO). COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: ethical considerations. Ginebra: WHO;2021. Disponible en: https://apps.who.int/iris/rest/bitstreams/1396234/retrieve. (Consultado en línea: 30 noviembre 2021).

  24. Saville M. COVID-19: release approved vaccines for trials of new ones. Nature. 2021;597(7875):178. doi: https://10.1038/d41586-021-02398-6.

  25. Park JJ, Thorlund K, Mills EJ. Critical concepts in adaptive clinical trials. Clin Epidemiol. 2018;10:343-51. doi: https://10.2147/CLEP.S156708.

  26. Liu M, Li Q, Lin J, Lin Y, Hoffman E. Innovative trial designs and analyses for vaccine clinical development. Contemp Clin Trials. 2021;100:106225. doi: https://10.1016/j.cct.2020.106225.

  27. World Health Organization (WHO). "Solidarity" clinical trial for COVID-19 treatments. [homepage on the internet]. Ginebra: OMS; c2020-10. Disponible en: https://www.who.int/emergencies/diseases/novel-coron avirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity clinical-trial-for-covid-19-treatments. (Consultado en línea: 21 agosto 2021.

  28. Agencia Europea de Medicamentos. Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines. Ámsterdam: EMA; 2020. Disponible: https://www.ema.europa.eu/en/news/global-regulators-discuss-data-requirements-phase-3-trials-covid-19-vaccines. (Consultado en línea: 27 diciembre 2021).

  29. Scheppler L, Clercq N, McGoldrick M, Dias J. Regulatory harmonization and streamlining of clinical trials applications globally should lead to faster clinical development and earlier access to life-saving vaccines. Vaccine. 2021;39:790-6. doi: https:// 10.1016/j.vaccine.2020.11.077.

  30. Abassi J. Homing in on a SARS-CoV-2 correlate of protection. JAMA. 2022; 327 (2): 115. doi: https://10.1001/jama.2021.24117.

  31. Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nature Medicine. 2021; 27: 1147-8. doi: https://10.1038/s41591-021-01432-4.

  32. Knezevic I, Mattiuzzo G, Page M, Minor P, Griffiths E, Nuebling M, et al. WHO international standard evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe. 2022;3(3):e235-e40. doi: https://10.1016/S2666-5247(21)00266-4.

  33. Wagner R, Meißner J, Grabski E, Sun Y, Vieths S, Hildt E. Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. Allergy. 2022; 77(1):72-82. doi: https://10.1111/all.14868.

  34. Ribeiro TB, Buss L, Wayant C, Nobre MRC. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018. PLoS One. 2020;15(7):e0236345. doi: https://10.1371/journal.pone.0236345.

  35. Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiol Drug Saf. 2015;24(7):709-15. doi: https://10.1002/pds.3793.

  36. Agencia Europea de Medicamentos (EMA). PRIME Priority Medicines. [homepage on the internet]. Ámsterdam: EMA; c2021-12. Disponible en: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines. (Consultado en línea: 10 diciembre 2022).

  37. Nagai S, Ozawa K. Regulatory approval pathways for anticancer drugs in Japan, the EU and the US. Int J Hematol. 2016; 104: 73-84. doi: https://10.1007/s12185-016-2001-7.

  38. Lythgoe MP, Middleton P. Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada. JAMA Netw Open.2021;4(6):e2114531. doi: https://10.1001/jamanetworkopen.2021.14531.

  39. Canada.ca. [homepage on the internet]. Otawa: Gobierno de Canadá; c2021-12. Disponible en: https://www. canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/prevention-risks/ covid-19-vaccine-treatment.html#a2. (Consultado en línea: 26 diciembre 2021).

  40. Romeu B, Sánchez C, Rodríguez Y. El enfoque regulador en la respuesta cubana contra la COVID-19. Rev Cubana Farm. 2020; 53 (3):e472. Disponible en: https://www.revfarmacia.sld.cu/index.php/far/article/view/472. (Consultado 28 diciembre 2021).

  41. Romeu B, Rodríguez Y, Bendiner S. The role of the Regulatory Science from the perspective of the Cuban Medicines Regulatory Agency: the impact of COVID-19 in promoting innovation, cooperation and scientific thinking. Ther Innov Regul Sci.2021; 55:1014-18. doi: https://10.1007/s43441-021-00300-0.

  42. World Health Organization. Regulatory collaboration: the International Coalition of Medicines Regulatory Authorities. WHO Drug Information, 2015;29(1):3-6. Disponible en: https://apps.who.int/iris/handle/10665/331082. (Consultado en línea: 30 noviembre 2021).




2020     |     www.medigraphic.com